Multicancer Blood Tests: 5 Key Things to Know

The landscape of cancer screening is undergoing a significant shift with the emergence of multicancer blood tests. These tests, designed to detect multiple cancer types from a single blood sample, represent a potentially groundbreaking approach to early detection. While not intended to replace existing, targeted screenings like mammograms or colonoscopies, they offer a new layer of vigilance, particularly for cancers lacking routine screening protocols. Here’s what you need to know about this evolving technology.

How Do These Blood Tests Work?

Multicancer detection tests, like the Galleri® test, don’t look for cancer cells themselves. Instead, they analyze blood for circulating tumor DNA (ctDNA) – fragments of DNA shed by cancer cells into the bloodstream. The premise is that even small amounts of this ctDNA can signal the presence of cancer, often before symptoms appear. The Galleri test, for example, aims to identify a signal shared by over 50 types of cancer. This approach differs from traditional screening methods, which focus on specific cancer types and often require imaging or biopsies for confirmation.

What Cancers Can They Detect?

Currently, these tests are designed to screen for a broad range of cancers, including those for which there are no standard screening recommendations. According to GRAIL, 7 in 10 cancer deaths arrive from cancers lacking recommended screening, such as pancreatic, liver, ovarian, and esophageal cancers. The Galleri test specifically looks for signals from many of these deadliest cancers. Although, it’s crucial to understand that these tests don’t detect all cancers, and not all cancers shed detectable DNA into the blood. False positive and false negative results are possible, and the tests are intended to be used in addition to, not as a replacement for, standard cancer screening practices recommended by healthcare providers.

What Does the Evidence Say?

The development of multicancer blood tests is relatively recent, and ongoing research is essential to fully understand their effectiveness. Early studies have shown promising results in detecting cancer signals, but it’s significant to consider the limitations. The Galleri test, for instance, has demonstrated performance in patients being screened for cancer, but the precise sensitivity and specificity – its ability to correctly identify those with and without cancer – are still being evaluated in larger, real-world populations. A key challenge is minimizing false positives, which can lead to unnecessary anxiety and further testing. The tests also may not be as effective in detecting cancers at very early stages or those that don’t readily release ctDNA into the bloodstream.

Who Might Benefit from These Tests?

Currently, multicancer blood tests are not universally recommended for everyone. They are most likely to be considered for individuals at higher risk of cancer, or those who may benefit from earlier detection due to limited access to traditional screening methods. Employers and health systems are also exploring offering these tests as part of broader wellness programs. However, the decision to undergo a multicancer blood test should be made in consultation with a healthcare provider, who can assess individual risk factors and discuss the potential benefits and limitations of the test. It’s important to remember that these tests are not a substitute for regular check-ups and recommended cancer screenings.

Understanding False Positives and Negatives

One of the most significant concerns surrounding multicancer blood tests is the potential for inaccurate results. A false positive means the test indicates cancer when none is present, leading to unnecessary follow-up tests and anxiety. A false negative means the test fails to detect cancer that is actually present, potentially delaying diagnosis and treatment. Both scenarios highlight the importance of interpreting test results cautiously and in conjunction with clinical evaluation. The tests are designed to be a screening tool, not a definitive diagnostic test, and any positive result requires further investigation to confirm the presence of cancer. The Galleri test specifically acknowledges that it does not detect a signal for all cancers and that false positive and false negative results do occur.

What’s on the Horizon?

The field of multicancer early detection is rapidly evolving. Researchers are working to improve the accuracy and reliability of these tests, as well as to expand the range of cancers they can detect. Future developments may include personalized testing approaches, tailored to individual risk factors and genetic profiles. Ongoing clinical trials are crucial to validate the effectiveness of these tests in diverse populations and to refine guidelines for their utilize. As more data becomes available, we can expect to see a clearer understanding of the role these tests will play in the future of cancer screening and prevention. For those interested in learning more or potentially accessing the Galleri test, information can be found at (833) 694-2553.